BATF2 and schistosomiasis: Altogether, our findings therefore strongly argue against a therapeutic target for the BATF2 blockade in the context of Type-2 controlled schistosomiasis in agreement with its recently reported anti-inflammatory role against pathological tissue Th17 responses during T. cruzi infection.7